Reviewing Summit Therapeutics PLC (SMMT) and Its Rivals
Summit Therapeutics PLC (NASDAQ: SMMT) is one of 294 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Summit Therapeutics PLC to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, analyst recommendations, risk and profitability.
Volatility and Risk
Summit Therapeutics PLC has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Summit Therapeutics PLC’s peers have a beta of 6.61, meaning that their average share price is 561% more volatile than the S&P 500.
This table compares Summit Therapeutics PLC and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Summit Therapeutics PLC||-12.44%||-29,334.40%||-7.61%|
|Summit Therapeutics PLC Competitors||-5,419.64%||-417.32%||-42.28%|
This is a summary of current recommendations for Summit Therapeutics PLC and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Summit Therapeutics PLC||0||0||3||0||3.00|
|Summit Therapeutics PLC Competitors||728||3173||11796||264||2.73|
Summit Therapeutics PLC presently has a consensus price target of $27.00, suggesting a potential upside of 111.60%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 28.45%. Given Summit Therapeutics PLC’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Summit Therapeutics PLC is more favorable than its peers.
Insider & Institutional Ownership
21.8% of Summit Therapeutics PLC shares are held by institutional investors. Comparatively, 51.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 16.8% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Summit Therapeutics PLC and its peers revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Summit Therapeutics PLC||$30.33 million||-$9.46 million||-36.46|
|Summit Therapeutics PLC Competitors||$473.33 million||$171.79 million||-7.05|
Summit Therapeutics PLC’s peers have higher revenue and earnings than Summit Therapeutics PLC. Summit Therapeutics PLC is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summit Therapeutics PLC peers beat Summit Therapeutics PLC on 7 of the 12 factors compared.
About Summit Therapeutics PLC
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.
Receive News & Stock Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related stocks with our FREE daily email newsletter.